Specialty Pharmacy

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

The data underscore the need for biomarker testing to identify patients who may be eligible for this therapy, according to physician from Memorial Sloan Kettering Cancer Center.

The drug from AstraZeneca and Ionis Pharmaceuticals demonstrates a sustained benefit through 66 weeks for those with hereditary transthyretin-mediated amyloid polyneuropathy.

Studies show that patients who are introduced to patient support programs through digital platforms are more likely to use support services.

Follow Pharmacy Times®’ live coverage of the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Phoenix, Arizona from March 29 to April 1, 2023.

Given the promising results, the company is advancing Rinvoq to a phase 3 clinical trial for the autoimmune disorder.

Remote work has been a growing trend across many different areas of pharmacy.

Akram Hussein, PharmD, MBA, BCNP, discusses the treatment process when treating a patient with prostate cancer with a radiopharmaceutical.

The portfolio of oral oncology products has evolved over the past few years and so has the traditional model of distribution.

Trastuzumab deruxtecan was approved by the FDA for HER2-low breast cancer treatment in 2022 and could also benefit some patients with hormone receptor-positive or triple-negative disease.

Trofinetide is the first and only drug approved for the treatment of Rett syndrome.

In part 2 of this panel discussion, experts discuss how they define traditional versus nontraditional oncology pharmacy roles and where roles within industry fit in.

Pharmacy departments can be one of the most expensive departments in a cancer center practice, but the revenue generated for its services typically far outpaces associated costs.

Cross-border collaborations are the way forward to make life-saving treatments more affordable and accessible to patients with rare diseases around the world.

In part 1 of this panel discussion, experts address how they define traditional versus nontraditional oncology pharmacy roles today, as well as the benefits and drawbacks of pursuing such a career path based on their experience.

Friedreich’s ataxia is a rare neuromuscular disease that affects approximately 5000 patients in the United States.

Sarilumab is a fully human monoclonal antibody indicated for patients with polymyalgia rheumatica who had an inadequate response to corticosteroids or are unable to tolerate corticosteroid taper.

The set of principles seeks to improve publication patterns to show the value of the pharmacist and how journals can strengthen pharmacy practice as a scientific discipline.

AI models can predict pharmacy foot traffic and peak service times, and even analyze patient histories to single out who picks up their prescriptions on time.

Understanding the complicated web of insurers, discounts from government and commercial plans, and payer access is extremely complicated.

Managing understaffing and increasingly demanding workflows is an ongoing challenge in pharmacy.

A specialty pharmacy can effectively dispense, monitor, and follow-up with transplant patients who are maintained on the standard triple-drug immunosuppression regimen.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.

The drive for personalized approaches to cancer have helped to create treatments for patients with rare cancers who have few, if any, options.

Study shows no robust differences in blood pressure, heart rate, lipids, and glucose measurements in children conceived using assisted reproductive technologies.

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in reduced bone loss.